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ABSTRACT
The transcriptional co-activator BOB.1/OBF.1 was
originally identified in B cells and is constitutively
expressed throughout B cell development. BOB.1/
OBF.1 associates with the transcription factors
Oct1 and Oct2, thereby enhancing octamer-
dependent transcription. In contrast, in T cells,
BOB.1/OBF.1 expression is inducible by treatment
of cells with PMA/Ionomycin or by antigen
receptor engagement, indicating a marked differ-
ence in the regulation of BOB.1/OBF.1 expression
in B versus T cells. The molecular mechanisms
underlying the differential expression of BOB.1/
OBF.1 in T and B cells remain largely unknown.
Therefore, the present study focuses on mechan-
isms controlling the transcriptional regulation of
BOB.1/OBF.1 and Oct2 in T cells. We show that
both calcineurin- and NF-iB-inhibitors efficiently
attenuate the expression of BOB.1/OBF.1 and Oct2
in T cells. In silico analyses of the BOB.1/OBF.1
promoter revealed the presence of previously un-
appreciated combined NFAT/NF-iB sites. An array
of genetic and biochemical analyses illustrates the
involvement of the Ca2+/calmodulin-dependent
phosphatase calcineurin as well as NFAT and
NF-iB transcription factors in the transcriptional
regulation of octamer-dependent transcription in
T cells. Conclusively, impaired expression of
BOB.1/OBF.1 and Oct2 and therefore a hampered
octamer-dependent transcription may participate
in T cell-mediated immunodeficiency caused by
the deletion of NFAT or NF-iB transcription factors.
INTRODUCTION
Regulated gene expression is a complex process, as dif-
ferent signals need to be integrated in a cell-type-specific
manner in accordance with the particular developmen-
tal stage and activation state. This complexity is
achieved by the architecture of a given promoter and/or
enhancer and therefore by the integrated action of differ-
ent transcription factors in conjunction with recruited
co-activators or -repressors. These proteins act together
on promoter DNA finally leading to the formation of
specific transcriptional complexes based on the DNA
sequence they bind as well on the activity of each com-
ponent itself.
The octamer element ATGCAAAT is one of such DNA
sequences and plays an important role in mediating
promoter activity of a large array of ubiquitous and
lymphocyte-specific genes. Octamer-dependent transcrip-
tion is achieved in first line by transcription factors that
belong to the Oct family. The selectivity of Oct factors
to octamer sequences and their transcriptional activity
can be enhanced by the recruitment of either ubiquitously
expressed or cell type-specific co-activators. For instance,
the histone H2B promoter activity depends on
Oct1 (Pou2f1) and its interaction with the transcriptional
co-activator OCA-S, a protein complex containing
GAPDH as a key component, whose expression is
highly increased during the S phase of the cell cycle (1).
In lymphocytes, the transcriptional co-activator BOB.1/
OBF.1 (B cell Oct binding factor 1/Oct binding factor 1;
Pou2af1) is responsible for the cell type-specific
octamer-dependent transcription. BOB.1/OBF.1 is re-
cruited to DNA by the interaction with Pit-1/Oct1,2/
Unc-86 domains of the ubiquitously expressed Oct1 or
the lymphocyte specific factor Oct2 (Pou2f2) (2–8), the
two Oct family members expressed in lymphocytes (9).
*To whom correspondence should be addressed. Tel: +49 7315 003 3846; Fax: +49 7315 002 2892; Email: cornelia.brunner@uni-ulm.de
2138–2154 Nucleic Acids Research, 2013, Vol. 41, No. 4 Published online 4 January 2013
doi:10.1093/nar/gks1349
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
However, not all octamer-regulated promoters depend
on the presence of BOB.1/OBF.1 (10,11). The ability of
Oct1 or Oct2 to recruit BOB.1/OBF.1 to the DNA might
be conferred by different octamer sequences that favor or
disfavor the ternary complex formation of these proteins
at the octamer motif (12). In addition, we and others
demonstrated that the presence of BOB.1/OBF.1 enables
Oct factors to bind to unfavorable non-consensus octamer
motifs (13,14). Together, the lymphocyte-specific regula-
tion of octamer-dependent transcription depends on an
appropriate DNA sequence, on the activity of Oct1 and
Oct2 transcription factors and on the presence of the tran-
scriptional co-activator BOB.1/OBF.1. Furthermore,
the latter is posttranslationally modified by phosphoryl-
ation at Ser184, which is required for its constitutively or
inducible transcriptional activity in B or T cells, respect-
ively (15).
The importance of octamer-dependent transcription is
underlined by the phenotypes of Oct1-, Oct2- and BOB.1/
OBF.1-deficient mice. The deletion of the ubiquitously ex-
pressed Oct1 protein leads to embryonic lethality (16), and
deletion of the lymphocyte specific Oct2 protein causes
death of newborn mice shortly after birth (17). Fetal
liver cell transfer into immuno-compromised mice
revealed that Oct1 is dispensable for B cell development
and function (18). In contrast, Oct2-deficient B cells are
unable to differentiate into immunoglobulin-secreting cells
(17). This phenotype is similar to that observed for
BOB.1/OBF.1-deficient mice. Although viable, these
mice are unable to form germinal centers on administra-
tion of T cell-dependent antigens. Hence, the production
of secondary immunoglobulins is severely compromised
(19–21). Besides missing germinal centers, BOB.1/
OBF.1/ mice show multiple defects at several stages of
B cell development (22–24). Although the relevance of Oct
proteins and BOB.1/OBF.1 for B cell development and
function cannot be dismissed, these proteins are also im-
portant for T cells. Functional octamer motifs could be
detected within the promoter regions of the chemokine
receptor CCR5 (25) as well as IL2 (26–30) and IL4
(28,31,32) genes. Also, the IFN promoter contains an
octamer motif that is bound by Oct proteins together
with BOB.1/OBF.1. As a consequence, the secretion of
IFN by BOB.1/OBF.1-deficient TH1 cells is reduced to
a level that disabled these mice to efficiently combat a
Leishmania major infection (33). Given the importance
of the octamer-dependent transcription for B and T cell-
development and function, it is, on the one hand, import-
ant to search for octamer-dependent target genes and, on
the other, to understand the regulatory mechanisms
underlying the octamer-dependent transcription itself.
Regulation of transcription is one major mechanism
to determine the capacity of a given protein. The pro-
moters of ubiquitously expressed Oct1 gene or the
lymphocyte-specific Oct2 gene have not been described
until today. In contrast, the BOB.1/OBF.1 promoter was
extensively studied to investigate its cis-acting elements
controlling its activity in B cells (34–36) where BOB.1/
OBF.1 is constitutively expressed at all stages of B cell
development (37), albeit at different levels. The highest
expression of BOB.1/OBF.1 was found in germinal
center B cells. Accordingly, signals important for
germinal center formation, like the stimulation with
anti-CD40 antibodies plus IL4, are able to increase the
expression of BOB.1/OBF.1 in vitro (38,39). In contrast,
in T cells BOB.1OBF.1 expression is inducible by treat-
ment of T cells with Phorbol 12-myristate 13-acetate
(PMA)/Ionomycin (P/I) or by antigen receptor engage-
ment (15,40), suggesting that different signals and
possibly also transcription factors might be responsible
for the expression of BOB.1/OBF.1 in B versus T cells.
Interestingly, also the expression of the lymphocyte-spe-
cific Oct2 protein is upregulated in activated T cells with a
kinetic similar to that obtained for BOB.1/OBF.1 (41,42).
As the expression and function of Oct proteins together
with BOB.1/OBF.1 was also found to be important for
the control of TH1 and TH2 immune responses (33), the
present study focuses on the regulation of octamer-
dependent transcription in T cells. Our analyses revealed
the involvement of the Ca2+/calmodulin-dependent phos-
phatase calcineurin (CN), as Oct2 and BOB.1/OBF.1
expression are efficiently suppressed in the presence
of the immunosuppressant cyclosporin A (CsA) or by
the siRNA-mediated suppression of CN-A. On T cell
receptor (TCR) stimulation, CN turned out to be a key
signaling molecule essential for the induction of both
Nuclear Factor of Activated T cells (NFAT) and NF-kB
transcription factors (43–45). CN dephosphorylates
NFAT transcription factors enabling them to translocate
into the nucleus where they control the expression of
numerous genes essential for T cell activation and differ-
entiation (46). In addition, CN is involved in the regula-
tion of the TCR-induced NF-kB signaling pathway by
regulating the complex assembly of Carma1, Bcl10 and
Malt1 by dephosphorylating Bcl10. Carma1, Bcl10 and
Malt1 complex formation is an essential prerequisite for
the activation of the IkB-kinase complex that in turn
phosphorylates the inhibitor of NF-kB (IkB) leading to
its proteasomal degradation. Consequently, cytosolic
NF-kB becomes released and translocates into the
nucleus where it regulates, similar to NFAT, the
promoter activity of numerous genes crucial for T cell
development, differentiation and function (46).
Therefore, both signaling pathways were analysed for
their capacity to mediate Oct and/or BOB.1/OBF.1 gene
expression and were identified as important regulators of
octamer-dependent transcription in T cells.
MATERIALS AND METHODS
Cell lines and culture
The Jurkat-4 x Octamer-Luc cell line was generated by
electroporation of Jurkat cells with a luciferase reporter
construct bearing four copies of the octamer motif cloned
earlier (47) together with a plasmid expressing the
Puromycin resistant gene (pSV-Puro) and selected by
Puromycin. Jurkat-NEMO/ was described (48). Jurkat
cells and derivates (Jurkat-4  Octamer-Luc, Jurkat-
NEMO/) and jNX amphotropic retrovirus producer
cells were cultured in Dulbecco’s modified Eagle’s
medium (Gibco, Invitrogen), containing 10% fetal calf
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serum (FCS) (Biochrome), 2mM of L-glutamine, 100U/
ml of penicillin and 100 mg/ml of streptomycin (Gibco,
Invitrogen) and 50 mM of b-mercaptoethanol at 37C
and 5% CO2. A3.01T cells and Namalwa B cells as well
as primary CD4+ cells were cultured in RPMI-1640
medium containing 10% FCS, 2mM of L-glutamine,
penicillin/streptomycin and 50 mM of b-mercaptoethanol
at 37C and 5% CO2.
CD4+ T cell isolation
Primary CD4+T cells were isolated from lymph nodes of
mice either by positive or negative selection using
magnetic microbead technology (Miltenyi).
Mice
C57BL/6 wild-type and TNFRI/p65 double-deficient mice
(and all their wild-type/heterozygous combinations) were
generated and obtained from our breeding facility. The
NFATc1/c2 double knockout mice were generated by
crossing the Nfatc2/ mouse (49) with the Nfatc1flx/flx
[described in (50)]Cd4-Cre mouse. Mice were analysed
3–4 or 10–12 weeks after birth, respectively.
Cell stimulation
Cells were stimulated in the presence of the following
agents: 100 ng/ml of CsA and 200 ng/ml of FK506 (CN
inhibitors), 1, 2 or 4 mMof Bay-117082 (a NF-kB inhibitor)
as indicated, 25 ng/ml of PMA, 500 ng/ml of Ionomycin,
200 nM of OH-tamoxifen (OHT) (all obtained from
Sigma-Aldrich), 15 or 30 mM of SB203580 (Upstate) as
indicated, 4 mg/ml of aCD3 and 0.5 mg/ml of aCD28
(BD). The NEMO-binding peptide and the NFAT inhibi-
tory peptide 11R-VIVIT were obtained from Calbiochem.
Promoter sequence analyses
In silico search for binding sites in BOB.1/OBF.1 pro-
moters of different species was performed using the
MatInspector tool (Matrix Family Library Version 8.3)
of the Genomatrix software tool (Genomatrix Company).
Electrophoretic mobility shift assays
Preparation of whole cell extracts for electrophoretic
mobility shift assays (EMSA) and the protocol of the
EMSA procedure have been described earlier (33). The
used oligonucleotides bearing the appropriate transcrip-
tion factor binding site were annealed and subsequently
labeled using 32P-adCTP in a fill in reaction. Sequences
are presented in the Supplementary Table S1.
Promoter cloning
The 1500 and 500 bp BOB.1/OBF.1 promotor constructs
were cloned into the pTKL/2 vector containing the
HSV-thymidine kinase promoter (105 to+52) from the
pBLCAT2 in front of the firefly luciferase coding region.
The HSV-thymidine kinase promoter was excised by a re-
striction endonuclease digest using HindIII and BglII and
replaced by the 1500 bp or 500 bp BOB.1/OBF.1 promoter
constructs cloned via genomic polymerase chain reaction
(PCR) using the following primers: mBOB.1/OBF.1prom
1500 bp 50 (HindIII): GCC AGG AAG CTT AGG GGT
TGA G; mBOB.1/OBF.1prom 1500 bp 30 (BglII): GCC
TTT TCT CTT TGA AGC AGA GAT CTT GGC TTC
TTT ACT. For amplification of the 500 bp promoter
fragment, the same 30 primer as for the 1500 bp
fragment was used in combination with the following
primer: mBOB.1/OBF.1prom 500 bp 50 (HindIII): GAC
CAA TGG TAA GCT TAG TCC TGC. Cloning of the
BOB.1/OBF.1 promoter mBOB.1/OBF.1prom 500 bp
construct was achieved using the following combination
of primers for genomic PCR: mBOB.1/OBF.1prom
1500 bp 50 (HindIII) as indicated earlier in the text,
together with mBOB.1/OBF.1prom 500 bp 30 (BglII):
CCA TTT ACA GGA CAG ATC TTA CCA TTG GTC.
The BOB.1/OBF.1 promoter mBOB.1/OBF.1prom
500 bp+TATA construct was generated by cloning of
an insert that was amplified by genomic PCR using the
following primers: mBOB.1/OBF.1prom 1500 bp 50
(HindIII): GCC AGG AAG CTT AGG GGT TGA G
and mBOB.1/OBF.1prom 500 bp 30 (HindIII): GCA
GGA CTA AGC TTA CCA TTG GTC, into the HindIII
site of the pTATA vector harboring the TATA box of the
HSV-thymidine kinase promoter from pBLCAT2 (38 to
+52) in front of the firefly luciferase coding region.
In vitro mutagenesis
Mutations of the predicted NFAT/NF-kB sites within the
BOB.1/OBF.1 promoter were generated using the
QuickChangeTM Mutagenesis kit (Promega). Primers
were ordered from Biomers, and sequences are provided
in Supplementary Table S4.
Transfection of cells
Transfections of Jurkat T and Namalwa B cells were per-
formed by electroporation (Bio-Rad) with 450V and
250 mF in phosphate buffered saline. The expression
vector for the constitutive active version of CREB
(c2CREB) is a kind gift of G. Tiel (51). Expression
vectors for NFATc1 and RelA/p65 have been described
(52,53). The pRL-CMV plasmid (Renilla Luciferase
control reporter vector; Promega) was cotransfected in
all experiments and used for normalization of different
transfection efficiencies in the individual experiments.
For suppression of CN A isoforms by siRNA, Jurkat T
cells were transfected with 75 nM of each SMARTpool
siRNA (CnBa: PPP3CA # L008300-0005; CnBb:
PPP3CB # L009704-0005) or with the appropriate concen-
tration of control siRNA (OnTARGETplus #
D001810-01-05) using the Nucleofection Kit V (Amaxa/
Lonza). The cells were subsequently incubated for 72 h
before analysis. Used SMARTpool siRNA were
obtained from Dharmacon.
Retroviral infection of cells
For virus production, the retroviral vectors expressing
NF-ATc1/aA-ER, NF-ATc1/aC-ER (54), IKK2-EE,
IKK2-KD (55) or the respective empty vectors were trans-
fected into the amphotropic jNX retrovirus producer
cells by use of the calcium phosphate method.
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Supernatant containing the retrovirus was collected 24 h
and 48 h after transfection and used to infect A3.01T cells
in the presence of 8 mg/ml of polybrene. At 2 consecutive
days, spin infection was performed at 2700 rpm (1300g)
and 37C for 120min. Positive cells were selected with
Zeocin until all cells were nearly 100% positive for green
fluorescent protein.
Western blots
For western blot analysis, 5–10 mg of total protein extracts
were separated on 12.5% polyacrylamid gels and
transferred onto nitrocellulose membranes (Schleicher&
Schuell). Membranes were blocked (TBS, 0.1% Tween,
5% milk); stained with anti-BOB.1/OBF.1 (Sigma),
Oct2, ERK2, IKK2 (Santa Cruz Biotechnology) and
NFATc1 (Alexis) antibodies followed by incubation with
HRP-coupled secondary antibodies (Pierce); and
visualized by enhanced chemiluminescence (Pierce).
Reverse transcriptase-PCR
Total RNA was isolated using Trizol reagent (Qiagen) and
reverse transcribed using moloney murine leukemia virus
reverse transcriptase (Roche). Quantitative PCR were per-
formed using qPCR-SYBR-Green (Roche). Primers
ordered from Biomers were designed using ‘Universal
Probe Library Assay Design Center’ Software (Roche).
Primer sequences are given in Supplementary Table S2.
Quantification of gene regulation was performed by the
Cp method using RPL13 as house-keeping gene.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were
performed using the ChIP-IT Express Chromatin
Immunoprecipitation Kit and the Re-ChIP-IT magnetic
chromatin re-immunoprecipitation kit from Active Motif,
according to the manufacturer’s protocol with slight
modifications: after enzymatic digestion for 10min, the
chromatin was sheared by two cycles of sonication (10
pulses each cycle) in the same buffer. The chromatin was
precleared for 2 h with protein G microbeads (Invitrogen)
and then incubated with rabbit polyclonal anti-p65
antibody sc-372 (2mg/ml; Santa Cruz Biotechnology),
mouse monoclonal anti-NFATc1 antibody 7A6 (4 mg/ml;
Alexis), mouse IgG (Dianova) or normal rabbit serum
(Pierce) at the appropriate concentrations for 4 h
followed by incubation with protein G microbeads for
1 h. The amount of precipitated DNA was evaluated by
quantitative PCR using the Roche Light Cycler LC480.
The used primers and primer positions are depicted in
Figure 6 and presented in Supplementary Table S3. The
relative amount of precipitated DNA was calculated using
the following formula: E(crossing point 1/10 total input crossing
point sample) and is depicted as amount of precipitated
genomic DNA relative to that precipitated by control
antibodies (mouse IgG or normal rabbit serum).
E=efficiency of the PCR determined by serial dilutions
of total input.
RESULTS
NFAT and NF-iB inhibitors restrain the inducible
expression of BOB.1/OBF.1 and Oct2 in T cells
To elicit the signaling pathways controlling the octamer-
dependent transcription in T cells, human Jurkat T cells
were stably transfected with a luciferase reporter construct
harboring four consecutive sequences bearing the octamer
binding motif ATGCAAAT in front of a luciferase gene.
As expected, the octamer activity was strongly
upregulated on treatment with P/I but remained un-
affected by stimulation with either P or I alone, suggesting
the requirement of a combined calcium influx and protein
kinase C activation for octamer-dependent transcription
in T cells (Figure 1A). Several transcription factors are
known to depend on such a combinatorial calcium and
protein kinase C signaling, including NF-kB and NFAT.
To further specify the signaling pathways controlling
octamer-dependent transcription, we used a panel of
specific pharmacological inhibitors. Indeed, complete sup-
pression of the inducible octamer activity was seen when
the cells were pre-treated with the CN inhibitor CsA. Also
the NF-kB inhibitor Bay11-7082 and the p38 inhibitor
SB203580 interfered with the inducible octamer activity,
although less efficiently. These data suggest that Ca2+/CN,
NF-kB and mitogen activated protein kinase-dependent
signaling pathways are involved in the regulation of
octamer-dependent transcriptional activity (Figure 1A).
We next wondered whether the same pharmacological
inhibitors could influence the activity of the known
BOB.1/OBF.1 promoter. Therefore, a reporter construct
harboring the previously described 1500 bp BOB.1/OBF.1
promoter (34) was transiently transfected into Jurkat
T cells, which were either left untreated or pre-treated
with inhibitors for CN, NF-kB or p38 for 30min before
the stimulation with P/I. These experiments revealed
that the BOB.1/OBF.1 promoter is sensitive to all of the
analysed inducers and inhibitors, similar to the
octamer-dependent reporter (Figure 1B). To explore
whether protein expression of BOB.1/OBF.1 mirrors its
promoter activity, Jurkat T cells and primary CD4+ cells
isolated from lymph nodes of C57BL/6 wild-type mice
were either left untreated or pre-treated for 30min with
the inhibitors used in the previous experiments and subse-
quently stimulated with P/I. Interestingly, we found a
striking coregulation of Oct2 and BOB.1/OBF.1 in
Jurkat (Figure 1C and D) and primary CD4+ T cells
(Figure 1E and F). Thus, the same inducers and inhibitors
control the expression of Oct2 and BOB.1/OBF.1 at
protein and mRNA levels. However, although the
BOB.1/OBF.1 expression was completely abolished by
treatment of Jurkat or CD4+ T cells with CsA even at
low concentrations (50–100 ng/ml), low levels of Oct2 ex-
pression were still detectable (Figure 1C and E). In
contrast, the NF-kB inhibitor Bay11-7082 had only a
moderate influence on BOB.1/OBF.1 and Oct2 expression
in Jurkat T cells even at high concentrations (2–4 mM),
whereas in primary CD4+ T cells, the inhibition of the
NF-kB pathway led to an almost complete abrogation
of Oct2 expression and to a marked reduction in BOB.1/
OBF.1 expression at low concentrations (1 mM) of the
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inhibitor. The insufficient block of BOB.1/OBF.1 and
Oct2 expression by Bay11-7082 might be owing to a
residual NF-kB activity, as seen in EMSA experiments
(Supplementary Figure S1). However, higher concentra-
tions of the inhibitor Bay11-7082 were toxic for primary
T cells. Also, pre-treatment of primary CD4+T cells with
CN inhibitors CsA or FK506 or by the NF-kB inhibitor
Bay11-7082 completely inhibited the strong BOB.1/OBF.1
and Oct2 induction seen after the more physiological
stimulation with anti-CD3 and anti-CD28 antibodies
(Figure 1G and H). The p38 inhibitor SB-203580 had a
moderate effect on BOB.1/OBF.1 and Oct2 expression
only at higher concentrations (Figure 1C), suggesting a
rather minor and/or indirect effect of p38 on the regula-
tion of octamer-dependent transcription in T cells.
Interestingly, EMSA studies (Supplementary Figure S1)
revealed that the NF-kB inhibitor Bay11-7082 inhibits
additionally NFAT binding to DNA and, vice versa, the
CN inhibitors CsA and FK506 interfere with NFAT
binding but also with the NF-kB signaling pathway, as
it was described recently (44,45). Therefore, the observed
effect of CsA and FK506 on BOB.1/OBF.1 expression is
not only mediated by inhibiting NFAT activity, as these
compounds also affect the activity of NF-kB, but rather
by the combined activity of NFAT and NF-kB. However,
treatment of murine primary CD4+ T cells or transfected
Jurkat cells with specific NFAT and NF-kB signaling
pathway inhibitors, like the NFAT inhibitory peptide
11R-VIVIT and the NF-kB essential modulator
(NEMO)-binding peptide, respectively, clearly
Figure 1. Inhibition of octamer function by CsA, p38 and NF-kB inhibitors in T cells. (A) A luciferase reporter construct bearing four copies of the
consensus octamer element was stabily transfected into Jurkat T cells. Cells were either left untreated or stimulated with P, I alone or together (P/I),
or were pretreated with CsA (100 ng/ml), SB203580 (20 mM) or Bay11-7082 (2mM) before the stimulation with P/I. Mean values ± s.d. of five
experiments are shown. (B and J) The 1500 bp BOB.1/OBF.1 promoter construct cloned in front of a luciferase gene was transfected together with
the appropriate empty vector (ev) into Jurkat T cells that were subsequently treated as described in (A) or as indicated. The determined relative
luciferase activity of the empty vector without stimulation was set one, and the fold increase of the promoter activity was calculated. Mean values ±
s.d. of three (in B) and two (in J) independent experiments are shown. The analyses of the pTATA promoter construct served as internal control. (C–
I) Jurkat or isolated primary CD4+T cells were treated as indicated. After 18 h of stimulation, cells were harvested. One part was used for protein
extraction and immunoblotting (C, E, G, I), and the other half was used for RNA isolation and quantitative RT-PCR (D, F, H) for the detection of
BOB.1/OBF.1 and Oct2 mRNA expression levels that were determined relative to the expression of the housekeeping gene RPL13. Analyses of
HPRT mRNA expression also normalized to RPL13 expression served as internal control (data not shown). The analyses of ERK2 expression (C, E,
G, I) served as loading control.
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demonstrates that both pathways are involved in the regu-
lation of BOB.1/OBF.1 expression via the regulation of
BOB.1/OBF.1 promoter activity (Figure 1I and J).
The BOB.1/OBF.1 promoter contains several binding sites
for NFAT and NF-iB
Previously, the BOB.1/OBF.1 promoter was analysed to
identify regulatory elements responsible for its activity in
B cells (34–36). In those studies, a functional cAMP
responsive element-binding protein (CREB)/Activating
Transcription Factor (ATF) site could be identified,
which is crucial for the B lymphocyte specific activity of
the promoter. In addition, a sequence related to a NFAT
binding site was described, however without any func-
tional relevance for the B cell-specific BOB.1/OBF.1
promoter activity. In search for possible additional tran-
scription factor binding sites using the Genomatrix
Software, we identified two combined NFAT/NF-kB
binding sites within the BOB.1/OBF.1 promoter. Both
newly identified sites are conserved between rat, mouse
and man, suggesting a possible functional relevance of
these regulatory elements. In contrast to B cells, where a
function of the predicted NFAT binding site has not been
revealed (34), an inducible complex formation could be
detected after P/I treatment of primary CD4+ T cells.
This complex resembles that formed at the NFAT site of
the IL2 promoter used in control experiments (Figure 2B,
lane 2; and C, lane 2). In addition, an inducible complex
formation could also be observed using the newly
identified combined composite and consecutive NFAT/
NF-kB sites of the BOB.1/OBF.1 promoter as probes
(Figure 2D and E, lane 2). In supershift experiments,
antibodies against NF-kB p50 were able to compete
against the observed inducible complexes formed at the
predicted NFAT/NF-kB binding sites within the BOB.1/
OBF.1 promoter (Figure 2D and E, lane 3) in a similar
way like anti-p50 antibodies prevent p50 binding to a con-
sensus NF-kB site (Figure 2F, lane 3). Interestingly,
anti-p50 antibodies are also able to interfere with the in-
ducible complex formed at the predicted NFAT site of the
BOB.1/OBF.1 promoter (Figure 2B, lane 3) and with the
NFAT binding observed at the IL2 promoter site (Figure
2C, lane 3). Similarly, anti-p65 antibodies interfere with
binding to the consecutive and composite NFAT/NF-kB
sites, which is comparable with the competition seen at the
consensus NF-kB site (Figure 2D, E and F, lane 4).
Additionally, anti-p65 antibodies also interfere with the
complex formation on the NFAT site of the BOB.1/
OBF.1 and IL2 promoters (Figure 2B and C, lane 4).
The use of NFATc1 antibodies reduces the binding to
the NFAT and NFAT/NF-kB sites of the BOB.1/OBF.1
promoter and generates supershifted complexes (marked
by clamp in Figure 2B, D and E, lane 5). Also, NFATc2
antibodies prevent complex formation to these specific
sites (Figure 2B, D and E, lane 6). Control experiments
using IgG antibodies or normal rabbit serum revealed the
Figure 1. Continued.
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specificity of antibody binding (Supplementary Figure S2).
Moreover, unlabeled oligonucleotides bearing the consen-
sus NFAT or NF-kB binding site could efficiently
compete against labeled NFAT or NFAT/NF-kB sites
identified in the BOB.1/OBF.1 promoter (Supplementary
Figure S2). Together, our data suggest that NFAT and
NF-kB family members are able to bind to all of these
newly identified potential cis-acting elements of the
BOB.1/OBF.1 promoter in vitro.
Newly identified NFAT/NF-iB binding sites contribute to
BOB.1/OBF.1 promoter activity
To demonstrate the importance of the potential NFAT
or NFAT/NF-kB binding site for the BOB.1/OBF.1
promoter activity, mutation analyses were performed. In
these experiments, specific point mutations were
introduced to prevent either NFAT or NF-kB binding
to these sites (Figure 3). Point mutation (G!T; Figure
3A) within the previously identified NFAT motif within
the BOB.1/OBF.1 promoter did not lead to alterations in
complex binding to this site. However, introduction of a
point mutation (G!T) within the second core motif for
NFAT and NF-kB clearly prevents inducible by P/I
complex formation, indicating the importance of this
residue within this potential transcription factor binding
site (Figure 3B). Within the consecutive NFAT/NF-kB
binding site of the BOB.1/OBF.1 promoter, both muta-
tions, preventing NF-kB (GG!TT) and NFAT binding
(CC!AA), abolish inducible complex formation on treat-
ment of T cells with P/I (Figure 3C). Therefore, both sites
possibly contribute to the inducible BOB.1/OBF.1
promoter activity in T cells. In contrast, although muta-
tions of critical residues within the NF-kB motif
Figure 2. Inducible complex formation on potential NFAT and NF-kB sites within the BOB.1/OBF.1 promoter. (A) Schematic representation of the
murine BOB.1/OBF.1 promoter. Indicated are the positions of the TATA box, of the CREB/ATF binding site and the positions/sequences of the
potential NFAT and NF-kB sites. (B–F) Primary murine CD4+ T cells were either left untreated or stimulated for 18 h with P/I. Whole protein
extracts were prepared and analysed in EMSA. In supershift experiments, the indicated antibodies were used.
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(GG!TT) of the composite NFAT/NF-kB site within the
BOB.1/OBF.1 promoter lead to a clear reduction of
complex binding on P/I treatment of CD4+ T cells,
mutations within the potential NFAT binding site
(CC!TT) slightly enhance the ability of complex
binding to this site (Figure 3D). For comparison, the
mutated consensus NFAT and NF-kB sites were also
analysed (Figure 3E).
Additionally, the introduction of mutations into the
1500 bp BOB.1/OBF.1 promoter construct that was
cloned in front of a luciferase gene and transfected into
Jurkat T cells (Figure 3F) revealed that all three newly
Figure 3. Mutation analyses of potential NFAT and NF-kB sites within the BOB.1/OBF.1 promoter. (A) Potential NFAT and NF-kB sites within
the BOB.1/OBF.1 promoter as well as consensus NFAT and NF-kB site were mutated as indicated and used (B–E) in EMSA experiments together
with whole cell extracts of isolated murine CD4+T cells that were either left untreated or were stimulated for 18 h with P/I as indicated. (F) Potential
NFAT and NF-kB sites within the BOB.1/OBF.1 promoter that was cloned in front of a luciferase gene were mutated as indicated. Mutated
constructs were transfected into Jurkat T cell that were subsequently stimulated with P/I over night. The percentage inhibition of promoter activity
was calculated relative to the activity of the wild-type 1500 bp BOB.1/OBF.1 promoter was set as 100%.
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identified NFAT and NFAT/NF-kB site are important for
full BOB.1/OBF.1 promoter activity, as mutation of each
reduces BOB.1/OBF.1 promoter activity by 15–20%.
Mutation of all three NFAT/NF-kB sites led to a reduc-
tion of BOB.1/OBF.1 promoter activity by 40%.
Interestingly, additional mutation of the previously
identified CREB/ATF site, important for BOB.1/OBF.1
promoter activity in B cells, almost completely abrogates
BOB.1/OBF.1 promoter activity in T cells.
A 500 bp sequence is necessary and sufficient for the
highest inducible BOB.1/OBF.1 promoter activity in
Jurkat T cells
For the full activity of the BOB.1/OBF.1 promoter in B
cells, a sequence spanning 1500 bp was identified (34). To
define regions important for the inducible activity in T
cells, additionally a shorter promoter construct was
generated encompassing 500 bp upstream of the start
site of transcription of the BOB.1/OBF.1 gene
(Figure 4A). To compare the behavior of these constructs
with respect to the basal and inducible BOB.1/OBF.1
promoter activity in B and T cells, the constructs were
transfected into Namalwa B or Jurkat T cells. In accord-
ance with previous findings (34), the 1500 bp promoter
showed the highest basal activity in Namalwa B cells
that could be further increased (3-fold) by treatment of
cells with P/I (Figure 4B and C). In B cells, the activity
of 500 bp construct was 3 times lower when compared
with the 1500 bp fragment with respect to basal and indu-
cible promoter activity. As expected, in T cells, no basal
BOB.1/OBF.1 promoter activity could be observed.
However, it was strongly induced when cells were
treated with P/I (Figure 4C). Notably, in T cells, the
500 bp promoter construct showed the highest inducibility
after P/I treatment (Figure 4B and C). The importance of
the 500 bp sequence of the BOB.1/OBF.1 promoter was
further underscored by deleting this promoter element,
which led to the complete loss of basal and inducible
BOB.1/OBF.1 promoter activity in B and T cells
Figure 4. The BOB.1/OBF.1 promoter spanning 500 bp is necessary and sufficient for full inducible activity in T cells. (A) Schematic representation
of the BOB.1/OBF.1 promoter. The positions of the analysed cis-elements and of the promoter fragments used in reporter assays are indicated.
(B and C) Namalwa B and Jurkat T cells were transiently transfected with the empty vector (ev) or with reporter constructs bearing either the
1500 bp or the 500 bp BOB.1/OBF.1 promoter construct or a deletion mutant of the longer version were the first 500 bp are missing (1500500 bp).
The relative luciferase activity (B) or the fold induction (C) of different promoter fragments was determined without or after stimulation of cells with
P/I, were in the second case the fold induction was determined relative to the luciferase activity of the empty vector without stimulation that was set
to one. (D) Jurkat T cells were transiently transfected with either the empty vector or the 1500 or 500 bp BOB.1/OBF.1 promoter constructs as
indicated, either alone or together with expression vectors for NFATc1, RelA or combination of both. Transfected cells were either left untreated or
stimulated subsequently with P/I. Next day, the cells were harvested to determine the relative luciferase activity. The relative luciferase activity
resulting from the transfection of the empty vector without induction was set to one. The fold induction relative to the empty vector was calculated
and is depicted. (B–D) Shown are the mean values± s.d. of three independently performed experiments.
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(Figure 4B and C). This loss of activity was not caused by
the deletion of regulatory elements necessary for the re-
cruitment of the basal transcriptional complex, as the
fusion of the same promoter construct to a TATA box
element of the thymidine kinase promoter did also not
lead to enhanced BOB.1/OBF.1 promoter activity in T
cells (Supplementary Figure S3).
To investigate the contribution of NFAT and NF-kB to
the BOB.1/OBF.1 promoter activity in T cells, Jurkat cells
were transfected with the 500 bp or 1500 bp BOB.1/OBF.1
promoter constructs, together with expression vectors
for NFATc1 or RelA/p65. Although overexpression of
NFATc1 had only a moderate effect, overexpression of
RelA/p65 already significantly enhanced the inducible
activities of the 1500 and 500 bp promoters. Coexpression
of both factors together leads to a further increase of
BOB.1/OBF.1 promoter activity, although this effect was
modest (Figure 4D). Again, the 500 bp promoter construct
was sufficient to achieve full BOB.1/OBF.1 promoter
activity induced by NFAT/NF-kB overexpression.
In B cells, the CREB/ATF site was found to be import-
ant for BOB.1/OBF.1 promoter activity. To investigate
whether this site is also important for the inducible expres-
sion of BOB.1/OBF.1 in T cells, the 1500 bp promoter
construct was transfected into Jurkat T cells, together
with expression vectors coding for NFATc1, RelA/p65
or a constitutive active version of CREB either alone or
in different combinations of these vectors. Also in T cells,
the CREB/ATF site seems to be of relevance, as
overexpression of a constitutive active CREB protein
leads to a significant increase of BOB.1/OBF.1 promoter
activity that was further enhanced by overexpression of
NFAT and NF-kB (Supplementary Figure S4). These
data together with our data obtained from EMSA and
transfection experiments in that the CREB site was
inactivated indicate that this CREB site is also of consid-
erable importance for BOB.1/OBF.1 promoter activity in
T cells.
Modulation of NFAT activity interferes with the
expression levels of BOB.1/OBF.1 and Oct2
One major regulator of NFAT activity is the Ca2+/
calmodulin-dependent protein phosphatase CN that
dephosphorylates cytosolic NFAT proteins. NFAT, in
turn, translocates into the nucleus where it binds to
DNA and regulates gene expression, a process that can
be efficiently inhibited by CsA. Down modulation of
CN by Amaxa transfection of siRNA directed against
the isoforms a and b of the catalytic subunit CN A
revealed a clear dependence of BOB.1/OBF.1 and Oct2
expression on CN activity (Figure 5A). Obviously,
Amaxa transfection of the indicated siRNA itself
pre-activated Jurkat T cells, as BOB.1/OBF.1 and Oct2
expression could be detected even in the unstimulated
state. However, the expression of both proteins could
be further enhanced by P/I treatment. Although the
downregulation of CN expression was incomplete, a
clear inhibition of inducible BOB.1/OBF.1 and Oct2 ex-
pression could be observed, indicating the importance of
CN for BOB.1/OBF.1 and Oct2 expression in T cells.
In peripheral T cells, mainly two members of the NFAT
family are expressed, NFATc1 and NFATc2. On T cell
activation, the NFATc1 isoform NFATc1/aA is predom-
inantly expressed (56). To study the influence of NFAT on
BOB.1/OBF.1 or Oct2 expression, human A3.01T cells
were retrovirally infected using vectors expressing either
the NF1ATc1/aA or NFATc1/aC isoform that were fused
to a part of the modified hormone binding domain of the
estrogen receptor a (ERa) (54), which is controlled by
OH-Tamoxifen (OHT). Although the OHT treatment of
cells infected with the empty vector left BOB.1/OBF.1 and
Oct2 expression unaffected, a significant increase in their
protein expression level could be observed when NFATc1/
aA or NFATc1/aC became functional active in the
presence of OHT (Figure 5B).To test whether the
absence of endogenous NFAT protein expression would
influence BOB.1/OBF.1 and Oct2 expression, CD4+ T
cells were isolated from Nfatc2/xNfatc1flx/flxxCD4-Cre
mice in which all T cells are devoid of the expression of
NFATc1 and NFATc2. After stimulation of purified
CD4+ T cells with either P/I or aCD3+aCD28 for 18 h,
the mRNA expression of BOB.1/OBF.1 and Oct2 was
analysed by quantitative PCR. The mRNA levels of
BOB.1/OBF.1 and Oct2 were sensitive to the combined
ablation of NFATc1 and NFATc2 protein expression
(Figure 5C and D), indicating the importance of these
factors for octamer-dependent transcription in T cells.
Modulation of NF-iB activity affects the expression levels
of BOB.1/OBF.1 and Oct2
Next, we investigated the influence of the NF-kB activity
on BOB.1/OBF.1 or Oct2 expression. First,
NEMO-deficient or wild-type Jurkat cells were stimulated
with P/I. Western blot analysis revealed a clear depend-
ence of BOB.1/OBF.1 expression on the presence of
NEMO in T cells (Figure 6A). NEMO is essential for
the canonical NF-kB signaling, as its deficiency leads
to a specific block of IKK (IkB kinase) activity (48).
Therefore, these findings clearly indicate a contribution
of NF-kB to the regulation of BOB.1/OBF.1 gene
transcription.
In another approach, human A3.01T cells were
retrovirally transduced using vectors expressing either a
constitutive active version (EE) or a kinase dead mutant
(KD) of IKK2 (55) (Figure 6B). In EMSA, the modula-
tion of NF-kB activity was monitored. Overexpression of
a kinase dead version of IKK2 led to a clear reduction in
the inducible NF-kB binding activity, whereas over-
expressing a constitutive active IKK2 led to an enhanced
basal and inducible NF-kB activity. In EMSA, a clear
correlation between NF-kB and Oct2 binding activity to
the appropriate consensus DNA binding sites could be
observed. Again, western blot analyses revealed a clear
dependence of the expression level of BOB.1/OBF.1 and
Oct2 on the level of NF-kB activity. To analyse the effect
of defective NF-kB activity on BOB.1/OBF.1 and Oct2
expression in vivo, we have used RelA/p65-deficient mice
that were bred into the TNFR type 1 (TNFRI; Tumor
Necrosis Factor Receptor I)-deficient background to
overcome the TNF-a-induced liver toxicity and embryonic
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lethality (57) observed in RelA/p65/ mice (58). CD4+T
cells were isolated from lymph nodes of mice deficient for
TNFRI and RelA/p65 (double knock out) or from mice
that were wild-type or heterozygous for one or the other
or both genes and stimulated with P/I for 18 h. When the
expression of RelA/p65 was abolished, the expression of
BOB.1/OBF.1 was almost completely restrained, whereas
Oct2 protein is still detectable, although the level of ex-
pression was severely reduced (Figure 6C). Together, these
data indicate an essential role of NF-kB signaling for the
induction of Oct2 and BOB.1/OBF.1 expression in T cells.
To address the question whether the loss or gain of NF-
kB or NFAT transcription factors leads to changes in
expression and/or binding activity of the other factor,
we have used the advantage of CD4+ T cells obtained
from mice bearing genetic mutations either for
NFATc1/NFATc2 or for TNFRI/p65. Additionally, we
overexpressed NFATc1A and RelA/p65 in Jurkat T cells
(Supplementary Figure S5). Interestingly, these experi-
ments revealed that the deletion or overexpression of
NFAT does not significantly lead to changes neither in
NF-kB p65 expression as seen in western blot ana-
lyses nor in NF-kB binding activity analysed in EMSA
experiments using a consensus NF-kB binding site
(Supplementary Figure S5A and C). However, deletion
of RelA/p65 in primary CD4+ T cells leads to a clear re-
duction of NFATc1 expression and consequently to a con-
siderable reduction in NFAT binding activity to the DNA
motif of the IL2 promoter. Vice versa, overexpression of
RelA/p65 in Jurkat cells clearly enhances NFAT binding
activity (Supplementary Figure S5B and C). These data
indicate that the observed effect on BOB.1/OBF.1 and
Oct2 expression in TNFRI/p65 double deficient murine
CD4+ T cells and in human Jurkat or A3.01T cells
Figure 5. CN and NFAT factors control the inducible BOB.1/OBF.1 and Oct2 expression in T cells. (A) Jurkat T cells were nucleoporated either
with scrambled siRNA or siRNA pools directed against the a and b isoforms of CN A subunit (CN A a+b). Subsequently, cells were stimulated for
8 h with P/I. Whole cell extracts were prepared and used for protein expression analyses of CN A a+b, BOB.1/OBF.1 or Oct2 by immunoblotting.
The detection of ERK2 expression served as loading control. (B) Human A3.01 T cells were infected retrovirally with vectors expressing either the
NF1ATc1/aA-ER or NFATc1/aC-ER or just the empty control vector (HA-ER). Afterwards, cells were either left untreated or treated with OHT, I,
P/I or with combinations of these inducers as indicated. After 18 h of stimulation, cells were harvested and subjected for immunoblotting, using
primary antibodies against NFATc1, BOB.1/OBF.1 and Oct2. The detection of ERK2 expression levels served as loading control. (C and D) Primary
CD4+T cells were isolated from wild-type (wt) or mutant mice in which the expression of NFATc1 and NFATc2 was simultaneously deleted in T
cells specifically (NFATc1c2-double knock out). After stimulation of cells with P/I or with aCD3+aCD28 antibodies for 18 h cells were harvested to
analyse BOB.1/OBF.1 and Oct2 expression at mRNA levels by quantitative RT-PCR. The relative mRNA expression levels are expressed relative to
that determined in unstimulated wild-type cells that were set as one. The experiments were performed twice in triplicates and using different dilutions
of the cDNA reveling the same result. One representative experiment is depicted as mean values± s.d.
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expressing various mutants interfering with NF-kB
signaling (Figure 6) could be mediated, at least in part,
also by changes in NFAT activity.
Analyses of contribution of NFAT and NF-iB to the
BOB.1/OBF.1 promoter activity in vivo
To clarify whether the observed NFAT and NF-kB effects
on BOB.1/OBF.1 and Oct2 expression are direct or rather
indirect, primary CD4+T cells were used in ChIP experi-
ments in which a fragment encompassing 189 bp from the
first 500 bp of the BOB.1/OBF.1 promoter containing the
already described NFAT binding site was analysed.
Additionally, a second fragment of 161 bp was analysed
containing the combined NFAT/NF-kB sites described
here. The locations of analysed binding sites and of
primers used for amplification of genomic DNA are
depicted in Figure 7A. After induction with P/I, both frag-
ments of the BOB.1/OBF.1 promoter could be efficiently
enriched by NFATc1 and RelA/p65 antibodies (Figure 7B
and C), indicating that NFAT and NF-kB transcription
factors exert a direct effect on the BOB.1/OBF.1
promoter.
DISCUSSION
Stimulation of the TCR triggers the activation of different
signaling cascades leading finally to the activation of
NFAT, NF-kB and AP-1, which act together with
several other transcription factors to orchestrate gene ex-
pression important for T cell function, survival, prolifer-
ation and differentiation. Oct2 and BOB.1/OBF.1 are
among these induced genes in activated T helper cells.
Owing to their ability to act in concert at the octamer
motif identified within the promoter region of the IFN
gene (33), BOB.1/OBF.1 and Oct2 are important for the
balanced TH1 and TH2 cytokine secretion by T helper
cells. While investigating signaling pathways, which
regulate octamer-dependent transcription, we found that
Figure 6. NF-kB activity influences BOB.1/OBF.1 and Oct2 expression levels in T cells. Wild-type (wt) or NEMO-deficient (NEMO/) Jurkat T
cells were stimulated for the time indicated with P/I or left untreated. The expression of BOB.1/OBF.1 was analysed by western blotting. (B) Human
A3.01T cells were retrovirally infected using vectors expressing either a constitutive active version of IKK2 (EE), a kinase dead version (KD) or the
empty vector (ev). After selection, cells were stimulated with P/I for 18 h and subsequently analysed for the protein expression levels of BOB.1/OBF.1
and Oct2 by western blotting (WB). The detection of IKK or ERK2 expression levels served as internal control or loading control experiments,
respectively. Additionally, the same extracts were used in EMSA to monitor the NF-kB and Oct2 binding activity to DNA using labeled consensus
sites. (C) Primary CD4+T cells of mice of the indicated genotype were either left untreated or stimulated with P/I for 18 h. Afterwards, the protein
expression levels of BOB.1/OBF.1 and Oct2 were analysed in immunoblots.
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Figure 7. NFAT and NF-kB transcription factors bind to different BOB.1/OBF.1 promoter regions in vivo. (A) The nucleotide sequence of the
analysed mouse BOB.1/OBF.1 promoter region is depicted. The NFAT and the predicted combined NFAT/NF-kB sites are shown. The position of
used primers for amplification of DNA fragments after chromatin immunoprecipitation are shown with bold, italic letters. Underlined letters indicate
the position of the TATA box. The start site of transcription is marked as+1. (B and C) Murine primary CD4+T cells were treated for 18 h with P/
I. The chromatin was cross-linked, sheared and immunoprecipitated using the indicated antibodies. Immunoprecipitations using mouse IgG or
normal rabbit serum served as negative controls. Immunoprecipitated DNA was purified and used as template in quantitative PCR reactions using
primers as indicated in (A) for the detection of fragments bearing either the NFAT site (B) or both combined NFAT/NF-kB sites (C). (D) As an
internal control, precipitated DNA was amplified using primers (Supplementary Table S3) located upstream of analysed potential NFAT and NF-kB
sites of the BOB.1/OBF.1 promoter.
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the expression of BOB.1/OBF.1 and Oct2 critically
depends on the expression and function of CN. Down
modulation or inhibition of the Ca2+/calmodulin-depend-
ent serine/threonine-specific protein phosphatase using
either siRNA or CsA attenuated the expression of both
proteins. The fact that CsA affects NFAT and NF-kB
activity (43–45) prompted us to investigate the involve-
ment of both signaling cascades in the regulation of
BOB.1/OBF.1 and Oct2 expression in T cells. Using
NEMO and NFAT inhibitory peptides, blocking the
NF-kB and the NFAT pathway in a specific manner,
revealed that both transcriptional activities are involved
that process.
Indeed, we found several transcription factor binding
sites within the BOB.1/OBF.1 promoter region conserved
between mouse and man that can be bound on stimulation
by both NFAT and NF-kB family members in vitro and
in vivo. The most distally located ‘composite’ NFAT/NF-
kB site (see Figure 2A) contains the classical NFAT core
motif TTTCC that is also found in the distal promoter of
the IL2 gene and an adjacent overlapping NF-kB binding
motif AGGTGT that was recently described as an active
NF-kB site within the human prostatic acid phosphatase
gene promoter (59). Composite NFAT/NF-kB binding
sites are described for numerous of promoters. For those
identified within the HIV LTR and the human IL8
promoter binding of NFATc2 as a homodimer has been
detected (60,61). Others have shown that NFATc2
competes for binding with NF-kB to the composite
NFAT/NF-kB site within the HIV LTR (62), indicating
that either NFAT or NF-kB factors bind to this site.
Indeed, there is no experimental evidence for a
heterodimer formation between NFAT and NF-kB
family members. Although in supershift experiments,
antibodies against NF-kB and NFAT are able to
prevent inducible complex formation on this composite
NFAT/NF-kB site, introduction of specific mutations
revealed that rather NF-kB than NFAT transcription
factors are bound to this site.
The second combined, ‘consecutive’ NFAT/NF-kB site
also contains the classical NFAT core motif TTTCC that
is followed at the 50 site by the sequence 50-GGGAATCG
CA-30. The latter represents the canonical NF-kB decamer
from position 1 to 6 and bears also a cytidine at position 9.
At such consecutive sites, NFAT and NF-kB complexes
can be formed simultaneously, not competing for binding
among each other. However, in Re-ChIP experiments, we
were not able to show the mutual binding of NFATc1
together with RelA/p65 (data not shown) to this site.
Yet, both the NF-kB and the NFAT motif are important
for transcription factor binding, as individual mutation of
both motifs prevents inducible by P/I complex formation.
The third important site for the regulation of BOB.1/
OBF.1 promoter activity is the already described
non-consensus NFAT binding site GAAGAAA that has
no functional relevance for the BOB.1/OBF.1 promoter
activity in B cells (34). In contrast, in T cells, an inducible
complex formation could be detected to this site in vitro.
Moreover, a 500 bp BOB.1/OBF.1 promoter construct
bearing this site was sufficient for full inducible
promoter activity in T cells that could be further
enhanced by cotransfection of expression vectors for
NFATc1 and RelA/p65. Cotransfection of both expres-
sion vectors together could further increase the promoter
activity in comparison with that achieved by an individual
overexpression of each factor, indicating that both cooper-
ate in the regulation of the 500 bp BOB.1/OBF.1 promoter
activity. Additionally, supershift experiments and chroma-
tin immunoprecipitations revealed a binding of both,
NFAT and NF-kB, to this part of the promoter. Hence,
a not-yet identified NF-kB binding site should be present
in close proximity to the mentioned non-canonical NFAT
site. Because of a high homology between the DNA
binding domains of NF-kB and NFAT family members,
they generate a similar conformation and therefore
contact identical nucleotides at the core motif GGAAA
(63). The non-canonical NFAT site GAAGAAA within
the BOB.1/OBF.1 promoter is followed by the sequence A
AAAAAG (Figure 2A). Both sites share high similarity
with the core sequence GGAAA to which both factors,
NF-kB and NFAT, are able to bind. The second motif
AAAG seems to be of biologically relevance, as the
point mutation G!T prevents inducible complex
binding in T cells. Possibly, this part of the BOB.1/
OBF.1 promoter is essential for the cooperative action
of NFAT and NF-kB necessary for the high inducible
activity of the 500 bp promoter.
Additionally, the CREB/ATF binding site, important
for the promoter activity in B cells (34), seems also to be
relevant in T cells, as overexpression of an active version
of CREB further increased the NFAT/NF-kB induced
BOB.1/OBF.1 promoter activity in Jurkat T cells,
whereas mutation of this site abrogates significantly
BOB.1/OBF.1 promoter activity. Therefore, the observed
decreasing effect of the p38 inhibitor SB203580 on the
BOB.1/OBF.1 promoter and on the activity of
octamer-dependent transcription in general could be
mediated by the inhibition of CREB and/or ATF-1 that
can also bind to the same site, as both factors need p38
kinase function for full transcriptional activity (64).
Otherwise, an inhibition of p38 could affect NFAT
proteins, as p38-mediated signaling activates NFATc1
(NFAT2) promoter activity and also increases its
mRNA stability (65).
Together, here we identified three different functional
NF-kB binding sites close to NFAT binding sites import-
ant for BOB.1/OBF.1 promoter activity. One of these NF-
kB sites (identified in the composite NFAT/NF-kB site)
was recently identified as an alternative NF-kB binding
site different from the canonical, the second (identified
in the consecutive NFAT/NF-kB site) shares high
homology to the canonical site; however, there are vari-
ations within the second kB half-site, and the third
(around the previously identified NFAT site) displays
similarities to just the core motif to which NFAT and
NF-kB proteins can bind. Indeed, deviations from the
consensus NF-kB site were described for several pro-
moters leading finally to the modulation of the affinity
of different factors of the family to the appropriate site
(66) and also influences the composition of the interacting
heterodimers bound [reviewed in (67)]. This leads to the
assumption that the expression of BOB.1/OBF.1 is
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differentially regulated under certain conditions, like
primary or secondary T cell activation or in different T
helper subtypes, by different homo- or heteromeric
complexes that are bound to one or the other NF-kB
site within the promoter.
The fact that the NF-kB sites identified here are in close
proximity to NFAT sites and thereby build either com-
posite or consecutive combined NFAT/NF-kB binding
motifs suggests that either NFAT or NF-kB complexes
or both together are able to transactivate the BOB.1/
OBF.1 promoter. This conclusion is in line with our
overexpression data, where the modulation of NFAT or
NF-kB activity alone has already significant influence on
BOB.1/OBF.1 and Oct2 expression. Additionally, the use
of specific inhibitory peptides revealed that both the
NFAT and the NF-kB signaling pathways are important
for BOB.1/OBF.1 promoter activity and BOB.1/OBF.1
expression in T cells. Otherwise, we were not able to
show simultaneous binding of both NFAT and NF-kB
factors in Re-ChIP experiments. The fact that the
deletion of RelA/p65 leads to a complete loss of BOB.1/
OBF.1 expression in primary CD4+ T cells, whereas the
deletion of NFATc1/c2 decreases BOB.1/OBF.1 expres-
sion by 50%, indicates that NF-kB activation is
possibly of higher importance for sufficient BOB.1/
OBF.1 expression in T cells than NFAT factors. But the
activity of NFAT and NF-kB depends on Ca2+oscillation
(68), which differs in different cell types, including TH1,
TH2 and TH17 T helper subpopulations (69,70). This
leads to distinct levels of NFAT and NF-kB nuclear lo-
calization and finally to differential cytokine expression by
different T helper subtypes. Therefore, it seems likely that
also the availability and activity of NFAT or NF-kB
family members in different T helper subpopulations or
under certain differentiation conditions may determine
whether the one or the other or both factors together con-
tribute to the BOB.1/OBF.1 promoter activity in vivo.
In fact, the regulation of BOB.1/OBF.1 expression in T
cells seems to be complex, as in natural regulatory T cells
(nTreg), its expression is down modulated (71), whereas in
T cells, which are energized or suppressed by nTreg, its
expression was found >10 times higher than in
non-suppressed CD4+ T cells (72). Although we have
already described the importance of BOB.1/OBF.1 for
balanced TH1/TH2 cytokine secretion (33), the precise
regulation of BOB.1/OBF.1 and Oct expression in differ-
ent T helper subpopulations that possibly affects the
induction of a different set of genes, remains to be
elucidated.
In summary, by an array of in vitro and in vivo
approaches, we provide evidences for the importance of
NFAT together with NF-kB transcription factors for the
regulation of octamer-dependent transcription in T cells.
Further work is required to identify the promoter region
and regulatory cis-acting elements responsible for the Oct2
gene regulation. Additionally, it will be interesting to
address the question whether the same transcription
factors/transcription factor binding sites, identified as im-
portant elements for the inducible BOB.1/OBF.1 expres-
sion in T cells, have also relevance for its basal and
inducible expression in B cells.
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